Search
Selected Filter
Filter Results
Displaying 21–30 of 199 research results for “stem-cells”
-
May 7, 2018
ARVO 2018: Dr. Henry Klassen Provides Update on jCyte Stem Cell Trials
Dr. Henry Klassen, jCyte co-founder and investigator at UC Irvine, provides an update on the clinical trials for an RP therapy derived from stem cells.
-
May 23, 2023
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
The Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
Jun 13, 2022
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
In its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
-
May 23, 2017
Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
In its fourth year, the meeting is becoming the world’s most comprehensive overview of the promising research underway for emerging IRD treatments.
-
Jan 19, 2022
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Company seeks to out-license its retinal progenitor therapy to a partner
-
Aug 10, 2022
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
-
May 13, 2020
jCyte Enters into Licensing Agreement with Santen Pharmaceutical for Cell Therapy
Emerging treatment designed to preserve vision for people with RP and related conditions
-
Apr 29, 2019
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
-
Feb 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Feb 21, 2019
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
ReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.